Complications in Process Simulation Execution
Regulators have exaggerated expectations for simulated media fills.
Regulators have exaggerated expectations for simulated media fills.
This article reviews aspects of media fill execution in which regulatory expectations have created artificial compliance concerns and significant practical difficulties.
Read this article in Pharmaceutical Technology's Biologics and Sterile Drug Manufacturing eBook.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing
May 2020
Pages: 10–14, 43
Citation
When referring to this article, please cite it as J. Agalloco, "Complications in Process Simulation Execution," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
